Fig. 3.
Fig. 3. Effect of cytokine treatment on human CD34+PBSC engraftment in the BM of NOD/SCID mice. / Human engraftment of 59 mice transplanted with 0.6 × 106CD34+ PBSCs and treated with TPO, SCF, and IL-3 (3C, n = 10); TPO, SCF, IL-3, IL-6, IL-11, and Fl3 (6C, n = 21); or without cytokines (PBS, n = 29) until time of sacrifice. The percentage of CD45+ human cells was determined by flow cytometry 2 (○), 4 (■), and 8 (●) weeks after transplantation. Each dot represents the level of human cells detected in the BM of a single engrafted (CD45+ cells > 0.5%) mouse. The engraftment rate was 80% ± 9% for the 3 groups. R = statistically significant difference (P = .03) in engraftment in the PBS group between weeks 2 and 8.

Effect of cytokine treatment on human CD34+PBSC engraftment in the BM of NOD/SCID mice.

Human engraftment of 59 mice transplanted with 0.6 × 106CD34+ PBSCs and treated with TPO, SCF, and IL-3 (3C, n = 10); TPO, SCF, IL-3, IL-6, IL-11, and Fl3 (6C, n = 21); or without cytokines (PBS, n = 29) until time of sacrifice. The percentage of CD45+ human cells was determined by flow cytometry 2 (○), 4 (■), and 8 (●) weeks after transplantation. Each dot represents the level of human cells detected in the BM of a single engrafted (CD45+ cells > 0.5%) mouse. The engraftment rate was 80% ± 9% for the 3 groups. R = statistically significant difference (P = .03) in engraftment in the PBS group between weeks 2 and 8.

Close Modal

or Create an Account

Close Modal
Close Modal